DIGNITANA

Dignitana is a commercial-stage medical device company focused on oncology supportive care through its flagship product, the DigniCap Scalp Cooling System. Having received the first FDA clearance for scalp cooling in the U.S. in 2015, the company has established a significant position in a growing niche market aimed at mitigating a distressing side effect of chemotherapy. In 2025, the company entered into a definitive agreement to be acquired by the Paxman Group, a move that will lead to its delisting from Nasdaq First North. This acquisition consolidates two leading players in the scalp cooling space, creating a combined entity with broader global reach and product offerings.

Patented scalp cooling system (DigniCap) using controlled hypothermia to reduce blood flow to hair follicles during chemotherapy, minimizing drug uptake and damage.

The scalp cooling market has historically included competitors like Paxman (pre-merger) and Penguin Cold Caps. The 2025 merger of Dignitana and Paxman significantly consolidates the landscape, creating a dominant player. Competition also exists indirectly from wigs, head coverings, and the status quo of no intervention.